EDIT

Editas Medicine Stock Price

32.17
0.00 (0.0%)
32.17
Best deals to access real time data!
Ultimate Trader (Monthly)
Monthly Subscription
for only
$80.29
Small Cap Basic
Monthly Subscription
for only
$33.03
Big Cap Pro
Monthly Subscription
for only
$52.04
VAT not included
Company Name Stock Ticker Symbol Market Type
Editas Medicine Inc EDIT NASDAQ Common Stock
  Price Change Change Percent Stock Price Low Price High Price Open Price Close Price Last Traded
1.49 4.86% 32.17 30.40 33.09 30.68 30.68 16:18:01
Bid Price Ask Price Spread Spread % News
31.75 32.44 0.69 2.13% - 2
Stock Trades Traded Volume VWAP Dollar Volume Average Volume 52 Week Range
9,047 1,052,665 $ 32.16 $ 33,856,857 1,306,648 14.01 - 36.78
Last Trade Time Type Quantity Stock Price Currency
16:16:53 5 $ 32.17 USD

Editas Medicine Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 2.00B 62.13M 60.13M $ 20.53M $ - -2.68 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - 0.00% - -

more financials information »

Editas Medicine News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical EDIT Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week29.1333.0928.6830.501,122,9353.0410.44%
1 Month26.7436.7824.9830.711,533,7745.4320.31%
3 Months22.7236.7821.4128.181,062,0549.4541.59%
6 Months30.0036.7814.0125.79998,0682.177.23%
1 Year24.0636.7814.0125.81851,2218.1133.71%
3 Years17.0445.0214.0127.61958,99315.1388.79%
5 Years18.0045.0212.4326.35804,33814.1778.72%

Editas Medicine Description

Editas Medicine Inc is a US-based genome editing company. It is engaged in treating patients with genetically defined diseases by correcting disease-causing genes. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company only operating segment being developing and commercializing genome editing technology.


Your Recent History
NASDAQ
EDIT
Editas Med..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.